Form 4: ANI Pharmaceuticals Director Sells Shares Under 10b5-1 Trading Plan

Muthusamy Shanmugam, a Director and Officer of ANI Pharmaceuticals, sold 700 shares of common stock at an average price of $76.83 on May 9, 2025, under a pre-arranged trading plan.

Summary

• On May 9, 2025, Muthusamy Shanmugam, a Director and Officer (Head of R&D, COO-Novitium Ops) of ANI Pharmaceuticals Inc., sold 700 shares of common stock.
• The sale was executed at a weighted average price of $76.83, with individual sales prices ranging from $76.11 to $76.95.
• The transaction was conducted under a Rule 10b5-1 trading plan adopted on September 18, 2024.
• Following the transaction, Shanmugam directly owns 92,588 shares of ANI Pharmaceuticals Inc.
• Shanmugam also indirectly owns 631,920 shares through Esjay LLC and 5,000 shares through SS Pharma LLC, over which he holds voting and dispositive power.

Sentiment

Score: 5

Explanation: Neutral sentiment as the transaction is a routine sale under a pre-arranged trading plan. It doesn't necessarily indicate a positive or negative outlook for the company.

Future Outlook

NA

Industry Context

Insider trading activity is always closely watched by investors. Sales by insiders can sometimes be interpreted negatively, but sales under a pre-arranged 10b5-1 trading plan are generally viewed as less concerning since they are planned in advance and not based on current inside information.

Stakeholder Impact

• The sale of shares by a company director could have a minor negative impact on shareholder sentiment, although the existence of a 10b5-1 plan mitigates this concern.

Key Dates

Keywords

ANI Pharmaceuticals, ANIP, Form 4, Insider Trading, Muthusamy Shanmugam, Rule 10b5-1, Share Sale, Director, Officer